Citywire for Financial Professionals

Citywire Selection


Invesco Perpetual Monthly Income Plus

Citywire Selection Verdict: There is an 80% allocation to bonds and nearly 20% exposure to equities, which is run by Ciaran Mallon. He recently replaced Neil Woodford on this part of the fund.

Experienced managers Paul Read and Paul Causer are responsible for the bond element. They believe core government bond markets offer limited value but have a significant position in bank bonds. This is a risky part of the market, but investors have been rewarded and should anticipate a more volatile ride than our other strategic bond picks.

The equity position gives exposure to solid blue chip equities such as pharmaceuticals giants GlaxoSmithKline and AstraZeneca and the fund yields just under 5%.

For more details view the latest factsheet.

Denotes a Star Pick, selected by Jon Miller - Head of research at Citywire

1 comments so far.  Why not have your say?

Len 885

16:34 | 14 Oct 2010

Ok but if u have held Glaxo for as long as I have [pre-mergers] the long term results have been poor- I would not buy them now- but I will hold mine just for yield.

Zeneca has been much better - original cost 615p -on same time scale, and excellent yield.

Len 885

Leave a comment

Protected by FormShield

Sorry, this link is not
quite ready yet